相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
50.0%
撤回
1
50.0%
暂无批准数据
- Race Oncology has identified that its lead cancer drug bisantrene (RCDS1) works by binding to G-quadruplex DNA and RNA structures, offering a novel approach to target the MYC oncogene. - The discovery addresses a decades-old challenge in oncology, as MYC is abnormally activated in over 70% of human cancers but has been considered "undruggable" due to its lack of conventional binding sites. - Understanding the precise mechanism of action significantly improves the drug's development outlook, regulatory approval chances, and commercial partnership potential. - The breakthrough enables Race Oncology to design more targeted clinical trials and identify cancer types most likely to respond to treatment.
- The provided source materials contain only disclaimer text from Kalkine Media without substantive content about pharmaceutical developments. - Both sources reference oncology companies Percheron Therapeutics and Race Oncology but lack specific clinical trial data or therapeutic details. - No actionable information about drug development, clinical outcomes, or regulatory milestones can be extracted from the available materials.
- Race Oncology discovered that bisantrene consists of three photoisomers with different biological and anticancer activities that rapidly interconvert upon exposure to visible light. - The company filed three patent applications covering the composition, manufacture, formulation and use of the active (E,E)-bisantrene isomer, potentially providing 20 years of patent protection. - Two patients were safely treated in the Phase 1 RC220 trial as single agent and in combination with doxorubicin, with recruitment expanding to Hong Kong and South Korea sites. - The discovery fundamentally changes the commercial prospects of the company according to CEO Daniel Tillett, with shares hitting a two-year high following the announcement.
- Race Oncology has filed three new patent applications after discovering that its lead cancer drug bisantrene contains three light-sensitive isomers, with only the (E,E)-bisantrene isomer showing significant anticancer activity. - The company has isolated and purified the active (E,E)-bisantrene isomer, eliminating the dosing variability and inconsistent outcomes that plagued earlier trials with mixed-isomer formulations from the 1980s. - If granted, the composition of matter patents would provide the strongest form of intellectual property protection until 2045, fundamentally changing Race's commercial prospects for its RC220 and RC110 formulations. - The breakthrough enables Race to revisit the original bisantrene formulation, which is already eligible for phase three trials in acute myeloid leukemia, significantly increasing clinical and commercial potential.
- Tryptamine Therapeutics has appointed Herwig Janssen, a former Johnson & Johnson executive with 40+ years of pharmaceutical experience, as its new non-executive chairman effective May 12. - The leadership change comes as Tryptamine prepares for pivotal clinical trials of TRP-8803, an IV-infused psilocin formulation being developed to treat binge eating disorder, fibromyalgia, and irritable bowel syndrome. - Chris Ntoumenopoulos will transition from non-executive to executive director, strengthening the company's leadership team ahead of key clinical and commercial milestones in psychedelic-assisted therapeutics.
- Race Oncology's stock jumped following the submission of a human ethics application for its RC220 Phase 1 solid tumour trial, with patient recruitment expected in Q1 2025. - Inoviq Ltd. reported successful disease specificity testing for its neuCA15-3 blood test, showing high sensitivity and specificity in detecting breast cancer across all stages. - Lumos Diagnostics Holdings Ltd. saw its shares rise after receiving approval for FebriDx reimbursement at US$41.38 per test by the United States Centers for Medicare and Medicaid Services.
- Race Oncology has submitted ethics and regulatory documents for a Phase 1 trial of RC220 with doxorubicin, targeting advanced solid tumors. - The trial, expected to begin in Q1 2025, will assess the safety and tolerability of RC220 in combination with doxorubicin across multiple sites. - The study includes two stages focusing on dose optimization, cardioprotective benefits, and anticancer efficacy of RC220. - Race Oncology also reported $18.78 million in cash reserves, with significant investment in R&D and drug manufacturing.
